CRBP

Corbus Pharmaceuticals Holding

CRBP.US corbuspharma.com
8.12
-0.12 (-1.46%)
USD · NASDAQ
52-week range
7.12
20.56
Trading at 7% of the 52-week range
Market Cap
159.37M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
5.48
Div. Yield
N/A
% Institutions
73.84%
% Insiders
1.24%

1 Year

-14.5%

3 Year

+20.1%

10 Year

-95.8%
Description

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Company Information

Company Name
Corbus Pharmaceuticals Holding
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US21833P3010
CIK: 0001595097
CUSIP: 21833P103
Currency: USD
Full Time Employees: 36
Phone: 617 963 0100
Fiscal Year End: December
IPO Date: Nov 11, 2014
Description:

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Address:

500 River Ridge Drive, Norwood, MA, United States, 02062

People

Directors & Officers

Name Title Year Born
Dr. Yuval Cohen Ph.D. CEO & Director 1975
Mr. Sean F. Moran CPA, M.B.A. Chief Financial Officer 1958
Dr. Ian Hodgson B.Sc., Ph.D. Chief Operating Officer 1973
Mr. G. Scott Goeken J.D., M.S. General Counsel & Corporate Secretary NA
Ms. Christina Bertsch M.A. Vice President of Human Resources NA
Mr. Nishant C. Saxena Chief Business Officer NA
Dr. Leonardo Viana Nicacio M.D. Chief Medical Officer 1978

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 03, 2026 Dominic Smethurst N/A Sale 3.29K $8.09 $26.58K
Feb 03, 2026 Ian Hodgson N/A Sale 2.42K $8.09 $19.54K
Dec 11, 2025 Cormorant Asset Management, Lp N/A Sale 30.03K $11.46 $344.13K
Oct 27, 2025 Yuval Cohen N/A Sale 8.97K $17.14 $153.80K
Oct 24, 2025 Sean F Moran N/A Sale 12.98K $17.02 $220.94K
Oct 24, 2025 Yuval Cohen N/A Sale 18.66K $17.01 $317.41K
Oct 20, 2025 Anne Altmeyer N/A Sale 1.06K $20.50 $21.73K
May 30, 2025 Anne Altmeyer N/A Sale 1.39K $7.25 $10.09K
May 30, 2025 John Kenneth Jenkins N/A Sale 2.78K $7.35 $20.46K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Cormorant Asset Management, LLC 2.34M Mar 31, 2026 12.12% $1.11 0.00%
Orbimed Advisors LLC 1.74M Mar 31, 2026 8.98% $0.32 8.76%
Aberdeen Group PLC 1.32M Jun 30, 2026 6.83% $0.02 0.00%
Vanguard Capital Management, LLC 734.11K Mar 31, 2026 3.80% $0.00 0.00%
Citadel Advisors Llc 727.06K Mar 31, 2026 3.76% $0.00 -13.77%
Jones Hill Capital LP 653.57K Jun 30, 2026 3.38% $1.30 0.00%
Prosight Management, LP 650.00K Jun 30, 2026 3.36% $1.05 -6.76%
Stonepine Capital Management Llc 383.46K Mar 31, 2026 1.98% $1.44 -1.66%
Armistice Capital, LLC 364.00K Mar 31, 2026 1.88% $0.06 -32.09%
Renaissance Technologies Corp 347.00K Mar 31, 2026 1.79% $0.01 -2.06%
Susquehanna International Group, LLP 333.42K Mar 31, 2026 1.72% $0.00 46.35%
ADAR1 Capital Management LLC 331.78K Mar 31, 2026 1.72% $0.18 15.69%
Diadema Partners LP 301.26K Jun 30, 2026 1.56% $0.36 -31.52%
BlackRock Inc 271.64K Mar 31, 2026 1.40% $0.00 1.34%
Dimensional Fund Advisors, Inc. 190.21K Jun 30, 2026 0.98% $0.00 39.25%
Geode Capital Management, LLC 187.03K Mar 31, 2026 0.97% $0.00 9.46%
Exome Asset Management LLC 184.91K Jun 30, 2026 0.96% $1.07 -21.02%
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 160.46K Mar 31, 2026 0.83% $0.00 -11.86%
Marshall Wace Asset Management Ltd 146.60K Mar 31, 2026 0.76% $0.00 89.04%
Persistent Asset Partners Limited 111.23K Mar 31, 2026 0.58% $0.39 1,588.57%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 abrdn Healthcare Investors 778.03K 4.02% ▲ 0.00% Jul 31, 2026
2 abrdn Life Sciences Investors 543.72K 2.81% ▲ 0.00% Jul 31, 2026
3 Biotech Growth Ord 538.60K 2.78% ▲ 0.00% May 31, 2026
4 Vanguard MStar Total Stk Mkt Idx Invest 533.58K 2.76% ▲ 0.00% Jul 31, 2026
5 iShares Russell 2000 ETF 400.82K 2.07% ▼ 0.57% Aug 31, 2026
6 Vanguard Institutional Extnd Mkt Idx Tr 197.65K 1.02% ▼ 5.12% Jul 31, 2026
7 Fidelity Small Cap Index 178.65K 0.92% ▲ 0.00% Jun 30, 2026
8 iShares Russell 2000 Value ETF 155.50K 0.80% ▼ 0.23% Aug 31, 2026
9 Global X Marijuana Life Sciences ETF 145.06K 0.75% ▲ 0.69% Jul 31, 2026
10 Russell 2000 Equity Index Fund B 106.00K 0.55% ▲ 0.00% Jun 30, 2026

Financial Highlights

Market Cap: $159.37M
EBITDA: $-106.68M
PEG Ratio: $0.00
Book Value: $5.48
Earnings/Share: $-6.11
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -53.00%
ROE (TTM): -95.58%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Valuation Metrics

Enterprise Value: $57.69M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 19.34M
Shares Float: 15.16M
% Insiders: 1.24%
% Institutions: 73.84%
Short % Float: 13.29%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-233.00K
Gross Profit
subtotal
$-233.00K
SG&A
adjust
$-15.22M
R&D
adjust
$-70.10M
Operating Income
subtotal
$-85.31M
Other / Non-Operating Items
adjust
$6.77M
Net Income
subtotal
$-78.54M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CRBP.US!